Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB160058 in Participants With Myeloproliferative Neoplasms
NCT06313593Phase 1Active, not recruiting
- Sponsor
- Incyte
- Start
- Aug 2024
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label trial of INCB160058 in myeloproliferative neoplasms (MPN) (4 arms), sponsored by Incyte. Primary endpoints: Dose Limiting Toxicities at 28 days, Treatment-emergent Adverse Events and 1 more. Started Aug 2024; status: active, not recruiting.
02
Drugs
INCB160058
03
Conditions
myeloproliferative neoplasms (MPN)
Beyond the preview
Go deeper on NCT06313593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06313593.